7.0 Date 
1. To demonstrate an improvement in progression free survival (PFS) in the 
1. To demonstrate an improvement in overall survival for ZACTIMA in combination 
2. To demonstrate an improvement in the overall objective response rate (ORR) 
4. To investigate the amount of resource used by subjects in terms of inpatient stays 
7. To investigate changes in subject weight 
4.7.3.4 Vital signs and physical examinations derivation or calculation of outcome 
6. STATISTICAL METHODS AND DETERMINATION OF SAMPLE 
1. INTRODUCTION 
1.1.2 ZACTIMA (ZD6474) 
1.1.2.1 Background 
1.1.2.2 Summary of adverse events (AEs) in previous studies 
1.2 Rationale for this study 
2.2 Secondary objectives 
2.3 Exploratory objectives 
3. STUDY PLAN AND PROCEDURES 
3.1 Overall study design and flow chart 
3.2.2 Risk/benefit and ethical assessment 
3.2.2.1 Docetaxel toxicity 
3.2.2.2 QTc prolongation 
3.2.2.3 Gastrointestinal toxicity 
3.2.2.4 Cutaneous toxicity 
3.2.2.5 Other toxicity 
3.3 Selection of study population 
3.3.1 Study selection record 
3.3.2 Inclusion criteria 
3.3.3 Exclusion criteria 
5. Mixed small cell and non small cell lung cancer histology 
28. Women who are pregnant or breast feeding 
3.3.4 Restrictions 
3.3.5 Withdrawal from study and discontinuation of treatment 
3.3.5.1 Withdrawal from study 
3.3.5.2 Procedures for withdrawal from participation in the study 
3.3.5.3 Discontinuation of treatment 
3.3.5.4 Procedures for discontinuation from study treatment 
3.4 Treatments 
3.4.1 Identity of investigational product and comparators 
3.4.2 Doses and treatment regimens 
3.4.2.1 ZACTIMA or placebo regimen 
3.4.2.2 ZACTIMA dose reduction 
3.4.2.3 Docetaxel 
3.4.3 Labeling 
3.4.4 Storage 
3.4.5 Accountability 
3.6 Blinding and procedures for unblinding the study 
3.6.1 Methods for ensuring blinding 
3.6.2 Methods for unblinding the study 
3.6.3 Methods for breaking the blind for monitoring of the safety 
3.7.1 Treatment for cancer 
3.7.1.1 Palliative Radiotherapy 
3.7.2 Other concomitant treatment 
3.8 Treatment compliance 
4. MEASUREMENTS OF STUDY VARIABLES AND 
4.1 Primary variable 
4.2 Screening and demographic measurements 
12 lead ECG 
4.3 Patient Reported Outcomes (PROs) 
4.3.1 FACT L questionnaire incorporating the LCS subscale 
4.3.1.1 Methods of assessment 
4.3.1.2 Derivation or calculation of variable 
4.3.2 Time to deterioration of disease related symptoms (TDS) 
4.3.2.1 Methods of assessment 
4.3.2.2 Derivation or calculation of variable 
4.3.3 Administration of ePRO/pPRO questionnaires 
4.4 Health Economic measurements and variables 
4.4.1 Resource data 
4.4.1.1 Methods of assessment 
4.4.1.2 Derivation or calculation of variable 
4.4.2 EQ5D 
4.4.2.1 Methods of assessment 
4.4.2.2 Derivation or calculation of outcome variable 
4.5 Pharmacokinetic measurements and variables 
4.5.1 Collection of pharmacokinetic samples 
4.5.2.1 ZACTIMA 
4.5.2.2 N desmethyl and N oxide metabolites 
4.6 Efficacy and pharmacodynamic measurement and variables 
4.6.1 Progression free survival (PFS) 
4.6.1.1 Methods of assessment 
4.6.1.2 Derivation or calculation of outcome variable 
4.6.2 Time to death 
4.6.2.1 Methods of assessment 
4.6.2.2 Derivation or calculation of outcome variable 
4.6.3.1 Methods of assessment 
4.6.3.2 Derivation or calculation of outcome variable 
4.6.4 Pharmacodynamic biomarker measurements and variables 
4.6.4.1 Methods of assessment 
4.6.4.2 Derivation or calculation of outcome variable 
4.6.5 Time to deterioration in patient WHO Performance Status (TDPS) 
4.6.5.1 Methods of assessment 
4.6.5.2 Derivation or calculation of variable 
4.7 Safety measurements and variables 
4.7.1 Adverse events 
4.7.1.1 Definitions 
4.7.1.2 Recording of adverse events 
4.7.1.3 Reporting of serious adverse events 
4.7.2 Laboratory safety measurements and variables 
4.7.2.1 Methods of assessment 
4.7.2.2 Derivation or calculation of outcome variables 
4.7.3.1 12 lead ECG methods of assessment 
4.7.3.2 12 lead ECG derivation or calculation of outcome variables 
4.7.3.3 Vital signs and physical examinations methods of assessment 
4.7.3.4 Vital signs and physical examinations derivation or calculation of outcome 
4.7.4 Other safety measurements and variables 
4.8 Volume of blood sampling and handling of biological samples 
6 Safety 
6.5 Visit 1 
4.8.1 Analysis of biological samples 
4.8.1.1 Clinical chemistry samples 
4.8.1.2 Pharmacokinetic samples 
4.9 Genetic measurements and co variables 
5. DATA MANAGEMENT 
6. STATISTICAL METHODS AND DETERMINATION OF 
6.2 Description of outcome variables in relation to objectives and 
6.3 Description of analysis sets 
6.4 Method of statistical analysis 
6.5 Determination of sample size 
6.6 Interim analyses 
6.7 Independent Data Monitoring Committee 
7.2 Audits and inspections 
7.3 Training of staff 
7.4 Changes to the protocol 
7.5 Study agreements 
7.6 Study timetable and end of study 
8.2 Ethical conduct of the study 
8.3 Informed consent 
8.4 Subject data protection 
9.1 AstraZeneca emergency contact procedure 
9.2 Procedures in case of medical emergency 
9.3 Procedures in case of overdose 
9.4 Procedures in case of pregnancy 
10. REFERENCES 
